Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CGTX with free AI briefings, catalyst countdowns, and dilution alerts.

CGTX · COGNITION THERAPEUTICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$30.8M Cash on Hand
29.2mo Cash Runway
Follow CGTX by email Get an email when CGTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CGTX, unsubscribe in one click. Privacy

📣 What CGTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Active Comparator CT1812 Age-Related Macular Degeneration Phase 2 · NCT05893537 Terminated
CT1812 Early Alzheimer's Disease Phase 2 · NCT05531656 Active not recruiting
Zervimesine Dementia With Lewy Bodies N/A · NCT06961760 No longer available

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CGTX holds $30.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 29.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CGTX files for a raise →

👥 Who Owns CGTX

Insiders 16.5% Institutions (79 holders) 23.5% Public and other holders 60%
HolderTypeShares% of sharesAs of
Aaron G.L. Fletcher
Director, 10% owner · +8,500 options
Insider 6,081,229 6.39% 2026-06-17
Leslie W. Kreis
Director, 10% owner · +8,500 options
Insider 6,048,500 6.36% 2025-06-18
Lisa Ricciardi
CEO & President, Director
Insider 1,754,702 1.85% 2026-04-16
Anthony Caggiano
Chief Medical Officer
Insider 874,906 0.92% 2026-04-16
John Brendan Doyle
Chief Financial Officer
Insider 618,942 0.65% 2026-05-01
Peggy Wallace
Director · +8,500 options
Insider 111,461 0.12% 2026-06-17
Ellen B Richstone
Director · +8,500 options
Insider 83,500 0.09% 2026-06-17
Jack A. Khattar
Director · +8,500 options
Insider 73,500 0.08% 2026-06-17
Brett P Monia
Director
Insider 73,500 0.08% 2026-06-17

Share count 95,100,822 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CGTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.